GlobalResearch and clinical trials
Venglustat phase 3 in late-onset Tay-Sachs and Sandhoff disease: no clinical benefit seen
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In the phase 3 trial, 40 adults received venglustat and 19 adults received placebo. After two years, the GM2 substance in the brain fluid fell by 48% with the drug and by 11% with placebo. But there was no difference on a test of hand skills. No new safety concerns were seen.
What does it mean for patients and families?
This is a negative result. Lowering the substance did not, on its own, mean a benefit for patients. This information will help guide the design of new studies.
Source
Scientific paper: Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials. Genetics in Medicine, 2026. DOI: 10.1016/j.gim.2025.101615 · PubMed 41108138
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Tay-Sachs disease, Sandhoff disease
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.